ACIP rec­om­mends rou­tine use of mpox vac­cine for at-risk adults, open­ing the door to po­ten­tial 2024 launch

The CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) has vot­ed in fa­vor of rou­tine use of the mpox vac­cine Jyn­neos, open­ing the door to po­ten­tial com­mer­cial op­por­tu­ni­ties for its man­u­fac­tur­er.

Bavar­i­an Nordic re­port­ed “over­whelm­ing” in­ter­est in Jyn­neos amid the glob­al mpox out­break. The two-dose vac­cine was one of the on­ly in­ter­ven­tions avail­able and of­ten the pre­ferred one, though it was on­ly rec­om­mend­ed for at-risk in­di­vid­u­als dur­ing an out­break.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER